Volume 65, Issue 11 , Pages 2136-2141, November 2007
Bone Morphogenetic Protein-Induced Repair of the Premaxillary Cleft
Purpose
The purpose of this study is to evaluate the bony regeneration of premaxillary clefts in humans using recombinant human bone morphogenetic protein type 2 in a collagen sponge carrier.
Patients and Methods
Twelve patients with unilateral clefted premaxillas were evaluated preoperatively and 4 months postoperatively. Ten patients were repaired with recombinant human bone morphogenetic protein type 2 while 2 others were grafted with anterior iliac crest particulate marrow cancellous bone. Computed tomographic studies were used to evaluate preoperative alveolar cleft volumes, postoperative bone bridge volumes, and preoperative and postoperative volume ratios.
Results
A preoperative and postoperative volume ratio for patients repaired with recombinant human bone morphogenetic protein type 2 ranged from 24.1% to 90.6% with a mean of 71.7%. Patients who were grafted with particulate marrow cancellous bone had similar preoperative and postoperative volume ratios ranging from 71.3% to 84.9% with a mean of 78.1%.
Conclusions
Clefts of the anterior maxilla can have complete osseous regeneration induced by recombinant human bone morphogenetic protein type 2 as an effective alternative to conventional anterior iliac particulate marrow cancellous bone grafts.
To access this article, please choose from the options below
PII: S0278-2391(07)01537-6
doi:10.1016/j.joms.2007.06.670
© 2007 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.
Volume 65, Issue 11 , Pages 2136-2141, November 2007
